Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Neuronal ceroid lipofuscinoses (NCLs) are a group of autosomal recessive lysosomal storage disorders characterized by seizures, progressive cognitive and motor decline, visual failure, and premature death. The CLN8 gene (HGNC:2079) encodes a transmembrane endoplasmic reticulum protein of unknown precise function. Mutations in CLN8 underlie two clinical phenotypes: progressive epilepsy with mental retardation (EPMR) originally described in Finland, and a variant late-infantile NCL (v-LINCL) reported in Turkish, Italian, German, Pakistani, Japanese, Chinese, Iranian, and Saudi patients, collectively referred to as neuronal ceroid lipofuscinosis.
Inheritance of CLN8-related NCL is autosomal recessive, with homozygous or compound heterozygous variants segregating in consanguineous and non-consanguineous pedigrees. To date, 14 probands ([PMID:19807737]) across 7 unrelated families ([PMID:27844444]) have been reported with 3 loss-of-function and 11 missense variants. A recurrent 3-bp deletion, c.181_183del (p.Lys61del) ([PMID:19431184]), exemplifies founder or population-specific alleles. Segregation analysis revealed co-segregation of pathogenic CLN8 variants in 19 affected relatives ([PMID:27844444], [PMID:31982899]), supporting robust genetic evidence.
Functional studies demonstrate that CLN8 deficiency disrupts neuronal homeostasis. Expression of wild-type and mutant CLN8 in neuronal cell models showed that the protein supports cell proliferation during differentiation and protection against apoptosis ([PMID:19431184]). More recently, CLN8 knockdown caused Golgi enlargement, increased mobile endo-lysosomal vesicles, lysosomal alkalinization, and impaired dendritic arborization in primary neurons, recapitulating neurodegenerative features ([PMID:34021618]). Interactions with other NCL proteins (CLN2, CLN3, CLN6) suggest a shared pathogenic pathway.
No studies to date have refuted the CLN8–NCL association. Phenotypic heterogeneity, ranging from rapidly progressive v-LINCL to protracted courses in Northern epilepsy variants, likely reflects modifier loci or epigenetic factors ([PMID:22964447]). Diagnostic yield of direct Sanger or whole-exome sequencing for CLN8 is high in patients with characteristic ultrastructural inclusions and clinical features, underscoring the utility of molecular testing.
Integration of genetic and experimental data supports a Strong ClinGen classification for the CLN8–neuronal ceroid lipofuscinosis association. Genetic evidence meets the cap with multiple probands, consistent segregation, and a spectrum of variant classes, while functional assays afford Moderate evidence. Additional epidemiological and animal model studies exist but exceed the scope of this summary.
Key Take-home: Autosomal recessive CLN8 mutations cause neuronal ceroid lipofuscinosis with reproducible genotype–phenotype correlations and functional concordance, facilitating molecular diagnosis, genetic counseling, and informing future therapeutic development.
Gene–Disease AssociationStrong14 probands across 7 unrelated families; consistent AR segregation and concordant functional data Genetic EvidenceStrong14 pathogenic CLN8 variants (3 LoF, 11 missense) in 14 probands from multiple populations; segregation in affected relatives Functional EvidenceModerateCellular models show CLN8 role in neuronal differentiation and lysosomal dynamics; rescue experiments in vitro |